Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

The use of GLP-1-agonists was associated with a significantly reduced risk of hospitalisation due to alcohol use disorder. Semaglutide was associated with a 36% lower risk, and liraglutide with a ...

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA ...

Introduction: Atrial fibrillation (AF) in patients with heart failure (HF) is associated with increased morbidity and mortality. Glucagon-like peptide-1 (GLP-1) agonists have been shown to reduce ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown notable advancements in managing blood sugar control. Nevertheless, there remains a gap in real-world data regarding the ...

Should they pan out in initial phase 1 testing, then the goal would be to combine them with GLP-1 agonist GSBR-1290 to treat patients with obesity. The third risk to consider would be in terms of ...

The global GLP-1 receptor agonist market is poised for extraordinary expansion, driven by an increase in therapeutic applications and favorable market projections. Recent analysis indicates a ...

Introduction: Anthracyclines are associated with cancer therapy-related cardiovascular dysfunction and heart failure (HF). The role of GLP-1 receptor agonists for patients with cancer undergoing ...